SavedAdd your journal

Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2014 / Cilt: 20 - Sayı: 6

Sıçanlarda bortezomib indüklü karaciğer hasarında B-1,3-(D)-glukan’ın hepatoprotektif etkileri

Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats

Osman Nuri KELEŞ
SERPİL CAN
Gülşen ÇIĞŞAR
SUAT ÇOLAK
HÜSEYİN SERKAN EROL
Nurhan AKARAS
BURAK ERDEMCİ
Bülent Çağlar BİLGİN
İSMAİL CAN
Bünyami ÜNAL
Mesut Bünyamin HALICI
Pages
929–938
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Administration of β -1,3-(D)-Glucan is efective in reversing tissue damage induced by bortezomib in rat livers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to evaluate the efects of β -1,3-(D)-glucan as an antioxidant and tissue protective agent and study the biochemical, histopathologic, and immunohistochemical efects of first therapeutic proteasome inhibitor bortezomib on the liver for treating relapsed multiple myeloma.
📊
Key Findings & Data:The experiment included 36 adult male rats, which were divided into four treatment groups: control (healthy); bortezomib-treated; β-1,3-D-glucan-treated; and bortezomib + β-1,3-(D)-glucan-treated.
💡
Conclusion & Impact:Administration of β -1,3-(D)-Glucan is efective in reversing tissue damage induced by bortezomib in rat livers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was to evaluate the efects of β -1,3-(D)-glucan as an antioxidant and tissue protective agent and study the biochemical, histopathologic, and immunohistochemical efects of first therapeutic proteasome inhibitor bortezomib on the liver for treating relapsed multiple myeloma. The experiment included 36 adult male rats, which were divided into four treatment groups: control (healthy); bortezomib-treated; β-1,3-D-glucan-treated; and bortezomib + β-1,3-(D)-glucan-treated. Each group was subdivided into two subgroups based on time of sacrifice (48 or 72 h). After the experiments, superoxide dismutase (SOD) activity and lipid peroxidation (LPO) amounts were determined, and immunohistochemical and histopathological changes were examined in all rat liver tissues. β -1,3-(D)-Glucan treatment normalized changes of LPO and stimulated an over activity of endogenous SOD. The results of the histopathologic parameters showed that treatment with β -1,3-(D)-Glucan in the bortezomib group ameliorated the development of non-specific reactive hepatitis (NSRH) and Kupfer cell activation via NF-kB. Administration of β -1,3-(D)-Glucan is efective in reversing tissue damage induced by bortezomib in rat livers.

Özet

Bu çalışmanın amacı, relaps multiple miyelom tedavi etmek için kullanılan ilk terapötik proteazom inhibitörü olan bortezomibin karaciğer üzerine immunohistokimyasal, histopatolojik ve biyokimyasal etkilerini araştırmak ve bir antioksidant ve doku koruyucu ajan olarak B-1,3-(D)-glukanın etkilerini değerlendirmekdi. Deney; kontrol (sağlıklı), bortezomib ile tedavi, B-1,3-(D)-glukan ile tedavi ve bortezomib + B-1,3-(D)-glukan ile tedavi olmak üzere dört tedavi grubuna bölünen 36 yetişkin erkek sıçan içerdi. Her bir grup sakrifikasyon zamanına (48 veya 72 saat) göre iki alt gruba ayrıldı. Deneylerin bitiminden sonra, süperoksit dismutaz (SOD) aktivitesi ve lipid peroksidasyon (LPO) miktarları ölçüldü ve tüm sıçan karaciğer dokularında immünohistokimyasal ve histopatolojik değişiklikler incelendi. B-1,3-(D)-glukan ile tedavi LPO değişikliğini normalize etti ve endojen SOD aktivitesi aşırı uyardı. Histopatolojik parametrelerin sonuçları, bortezomib grubunda B-1,3-(D)-glukan ile tedavi NF-kB yoluyla Kupfer hücre aktivasyonunu ve non-spesifik reaktif hepatit (NSRH) gelişimini regüle ettiğini gösterdi. B-1,3-(D)-glukan uygulaması, sıçan karaciğerinde bortezomibin neden olduğu geri döndürülebilir doku hasarında efektifdir.

🔖

Cite This Article

KELEŞ, O. N., CAN, S., ÇIĞŞAR, G., ÇOLAK, S., EROL, H. S., AKARAS, N., ERDEMCİ, B., BİLGİN, B. Ç., CAN, İ., ÜNAL, B., HALICI, M. B. (2014). Sıçanlarda bortezomib indüklü karaciğer hasarında B-1,3-(D)-glukan’ın hepatoprotektif etkileri. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 20 - Sayı: 6, 929–938. https://ajindex.com/articles/272751

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Demasi M, Netto LE, Silva GM, Hand A, de Oliveira CL, Bicev RN, Gozzo F, Barros MH, Leme JM, Ohara E: Redox regulation of the proteasome via S-glutathionylation. Redox Biol, 14 (2): 44-51, 2013
  2. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S: Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes, 62 (3): 811-824, 2013
  3. Yerlikaya A, Erin N: Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med, 22 (6): 817-823, 2008
  4. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S: Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer, 7 (40): 1-14, 2008
  5. Voorhees PM, Dees EC, O’Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res, 9 (17): 6316-6325, 2003
  6. Elliott PJ, Zollner TM, Boehncke WH: Proteasome inhibition: A new anti-infammatory strategy. J Mol Med (Berl), 81(4): 235-245, 2003
  7. James SE, Dunham M, Carrion-Jones M, Murashov A, Lu Q: Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin. Neurotoxicology, 31 (2): 188-194, 2010
  8. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites. Drug Metab Dispos, 33 (6): 771-777, 2005
  9. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S: Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes, 62 (3): 811-824, 2013
  10. Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS: Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos, 34 (4): 702-708, 2006
  11. Amin A, Hamza AA: Oxidative stress mediates drug-induced hepatotoxicity in rats: A possible role of DNA fragmentation. Toxicology, 208 (3): 367-375, 2005
  12. Block KI, Koch AC, Me